Clinical Trials Logo
  1. Home
  2. Vestibular Schwannoma
  3. NCT03593577

Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI

Vestibular Schwannoma Clinical Trial

Official title:
Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI

Clinical Trial Summary

Endolymphatic hydrops is well known of the lay public in its primary form that is Ménière disease. Nowadays, the best w ay to approach it in vivo, is to use magnetic resonance imaging (MRI).

However, endolymphatic hydrops don't limit itself to its primary form but cover a whole range of pathologies.

The hypothesis is that patients with vestibular schwannomas are more likely to develop secondary saccular hydrops.

The aim is to compare high-resolution T2-weighted images of the saccule in patients followed up for vestibular schwannomas with healthy volunteers and histological sections from cadavers in order to identify its changes.

The secondary purpose of The protocol is to determine if vestibular and audiometric abnormalities could be related to this secondary hydrops more specifically than to the tumor size and localisation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03593577
Study type Observational
Source University Hospital, Strasbourg, France
Contact Aïna VENKATASAMY,, MD
Phone 33 3 88 12 78 65
Email aina.venkatasamy@chru-strasbourg.fr
Status Recruiting
Phase
Start date June 1, 2018
Completion date June 2019
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Active, not recruiting NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Completed NCT03210285 - WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data